A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week ...
Upstream Bio Inc. UPB shares are trading lower during Friday’s session as the stock reacts to recent developments in its ...
Upstream Bio, Inc. UPB shares were trading higher during Wednesday’s premarket session following positive results from the Phase 2 VALIANT trial of verekitug, a treatment for severe asthma. The stock ...
Upstream Bio (UPB) stock fell 12% despite a Phase 2 trial success for the company's asthma drug verekitug. Read more here.
Upstream Bio has sailed to a phase 2 win in sinusitis and plans to push its candidate forward against a competitive current. Investigators randomized 81 adults with chronic rhinosinusitis with nasal ...
Upstream Bio, Inc. downgraded despite strong Verekitug phase 2 asthma results; assess anti-TSLP competition, dosing edge & catalysts. Click for this UPB update.
Investing.com -- Upstream Bio (NASDAQ:UPB) stock fell 23% after the company reported mixed results from its Phase 2 VALIANT trial of verekitug for severe asthma treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results